What’s New in Psoriasis - 07/03/19

Doi : 10.1016/j.det.2018.11.001

Stephanie von Csiky-Sessoms, Mark Lebwohl, MD ^⁎
The Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, 5th Floor, New York, NY 10029, USA

^∗Corresponding author.

Resumen

Psoriasis is a common, chronic inflammatory skin disease that is characterized by the formation of sharply demarcated, scaly, erythematous plaques. It affects about 2.2% of the population in the United States and has a large impact on patient quality of life. Many advances have been made in the last few years in the management of psoriasis. Proinflammatory cytokines play major roles in the pathogenesis of disease. Biologic medications targeting the aforementioned cytokines have been developed and studied for the management of psoriatic disease. This article summarizes the newest findings in the management of psoriasis and the various treatment options available.

El texto completo de este artículo está disponible en PDF.

Keywords : Psoriasis, Treatment, Interleukin-23, Interleukin-17, TNF-α, Biologic

Esquema

Key points

Interleukin-23–targeted therapies

Interleukin-17–targeted therapies

Tumor necrosis factor–targeted therapies

Disclosure Statement: M. Lebwohl is an employee of Mount Sinai, which receives research funds from Abbvie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, Johnson & Johnson, Kadmon, MedImmune, AstraZeneca, Novartis, Pfizer, and ViDac, and is also a consultant for Allergan, Leopharma, and Promius. S. von Csiky-Sessoms has no conflicts of interest.